PACAP/PAC1-R activation contributes to hyperalgesia in 6-OHDA-induced Parkinson's disease model rats via promoting excitatory synaptic transmission of spinal dorsal horn neurons

Acta Pharmacol Sin. 2023 Dec;44(12):2418-2431. doi: 10.1038/s41401-023-01141-3. Epub 2023 Aug 10.

Abstract

Pain is a common annoying non-motor symptom in Parkinson's disease (PD) that causes distress to patients. Treatment for PD pain remains a big challenge, as its underlying mechanisms are elusive. Pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptor PAC1-R play important roles in regulating a variety of pathophysiological processes. In this study, we investigated whether PACAP/PAC1-R signaling was involved in the mechanisms of PD pain. 6-hydroxydopamine (6-OHDA)-induced PD model was established in rats. Behavioral tests, electrophysiological and Western blotting analysis were conducted 3 weeks later. We found that 6-OHDA rats had significantly lower mechanical paw withdrawal 50% threshold in von Frey filament test and shorter tail flick latency, while mRNA levels of Pacap and Adcyap1r1 (gene encoding PAC1-R) in the spinal dorsal horn were significantly upregulated. Whole-cell recordings from coronal spinal cord slices at L4-L6 revealed that the frequency of spontaneous excitatory postsynaptic currents (sEPSCs) in dorsal horn neurons was significantly increased, which was reversed by application of a PAC1-R antagonist PACAP 6-38 (250 nM). Furthermore, we demonstrated that intrathecal microinjection of PACAP 6-38 (0.125, 0.5, 2 μg) dose-dependently ameliorated the mechanical and thermal hyperalgesia in 6-OHDA rats. Inhibition of PACAP/PAC1-R signaling significantly suppressed the activation of Ca2+/calmodulin-dependent protein kinase II and extracellular signal-regulated kinase (ERK) in spinal dorsal horn of 6-OHDA rats. Microinjection of pAAV-Adcyap1r1 into L4-L6 spinal dorsal horn alleviated hyperalgesia in 6-OHDA rats. Intrathecal microinjection of ERK antagonist PD98059 (10 μg) significantly alleviated hyperalgesia in 6-OHDA rats associated with the inhibition of sEPSCs in dorsal horn neurons. In addition, we found that serum PACAP-38 concentration was significantly increased in PD patients with pain, and positively correlated with numerical rating scale score. In conclusion, activation of PACAP/PAC1-R induces the development of PD pain and targeting PACAP/PAC1-R is an alternative strategy for treating PD pain.

Keywords: PAC1-R; Parkinson’s disease; hyperalgesia; pituitary adenylate cyclase-activating polypeptide; sEPSCs; spinal cord dorsal horn.

MeSH terms

  • Animals
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Humans
  • Hyperalgesia / drug therapy
  • Hyperalgesia / metabolism
  • Oxidopamine
  • Pain
  • Parkinson Disease* / drug therapy
  • Pituitary Adenylate Cyclase-Activating Polypeptide* / metabolism
  • Pituitary Adenylate Cyclase-Activating Polypeptide* / pharmacology
  • Posterior Horn Cells / metabolism
  • Rats
  • Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I / metabolism
  • Synaptic Transmission

Substances

  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Oxidopamine
  • Extracellular Signal-Regulated MAP Kinases
  • Adcyap1r1 protein, rat
  • Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I